News

TORONTO, CANADA — (September 15, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that Dan Legault, Antibe’s Chief Executive Officer, will present a corporate overview at the upcoming virtual Oppenheimer Fall Healthcare Life Sciences … Continued

TORONTO, CANADA — (August 31, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences: LD Micro 500 – Virtual Event September 1, 2020 – 12:20pm (Eastern Time) ld500.ldmicro.com Antibe has also been invited to participate in the TSX Venture 50™ Capital Conference for the … Continued

TORONTO, CANADA — (August 24, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. The Company’s unaudited fiscal Q1 2021 condensed interim consolidated financial statements and MD&A are available on SEDAR. About Antibe Therapeutics Inc. Antibe develops safer, … Continued

TORONTO, CANADA — (August 20, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information circular (the “Circular”) were approved, including: The election of directors (Roderick Flower, Amal Khouri, Daniel Legault, Walt Macnee, John … Continued

TORONTO, CANADA — (August 6, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support efforts to broaden visibility within the US capital markets. “We are excited to have engaged Stern IR as our new investor … Continued

 – Phase II secondary data confirmed remarkable potency of ATB-346 – – 3rd party commercial studies project peak annual sales of $5.3 billion across seven key countries – – Large market partnering efforts to accelerate in parallel with Phase III program – – Non-opioid painkiller advancing towards the clinic; pipeline expansion initiatives underway – TORONTO, … Continued

TORONTO, CANADA — (July 24, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. The Company’s audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. About Antibe Therapeutics Inc. Antibe develops safer, … Continued

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (June 30, 2020) — Antibe Therapeutics Inc. (TSXV: ATE) announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the “Units“) at a price of $0.40 per Unit (the “Offering Price“) plus … Continued

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (June 9, 2020) — Antibe Therapeutics Inc. (TSXV: ATE) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Bloom Burton Securities Inc. and including Echelon Wealth Partners Inc., Paradigm Capital … Continued

TORONTO, CANADA — (June 2, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) will host a conference call Thursday, June 4 at 10:00 am ET to discuss the recent positive results of the Phase 2B dose-ranging, efficacy study for ATB-346. Management will provide a brief summary of the results followed by a Q&A session … Continued

– ATB-346 demonstrates superiority to placebo in reducing osteoarthritis pain – – ATB-346 is more potent than expected; lowest effective dose still to be established – – Antibe plans pivotal Phase 2/3 adaptive registration trial – TORONTO, CANADA — (June 1, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that … Continued

– Dr. Joseph Stauffer, an anesthesiologist with deep clinical and regulatory experience, fills a key position as Antibe prepares for late-stage development and partnering – TORONTO, CANADA — (May 6, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the hiring of Dr. Joseph Stauffer in the new role of Chief … Continued

– Top-line data expected within six weeks – TORONTO, CANADA — (May 4, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today provides an update on the timing of top-line results for the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. Involving 360 patients across 40 clinical sites, this study is one … Continued

TORONTO, CANADA — (February 28, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that the last patient has been enrolled and is on treatment in the Phase 2B dose-ranging, efficacy study of Antibe’s lead drug, … Continued

TORONTO, CANADA — (February 25, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended December 31, 2019. … Continued

TORONTO, CANADA — (February 24, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the publication of a multi-national study entitled “Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide-Releasing Anti- Inflammatory Drug (ATB-352): … Continued

TORONTO, CANADA — (February 21, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that it has been named a TSX Venture 50™ company for the second consecutive year, in recognition of its performance on the … Continued

TORONTO, CANADA — (January 13, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the hiring of Dr. Rami Batal in the new role of Senior VP, Commercial Strategy. The creation of this position represents a … Continued